(-)-1-(benzofuran-2-yl)-2-propylaminopentane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (-)-1-(benzofuran-2-yl)-2-propylaminopentane
• 英文别名: 1-(benzofuran-2-yl)-2-propylaminopentane；Benzofuranylpropylaminopentane；1-(1-benzofuran-2-yl)-N-propylpentan-2-amine
• 化学式: C₁₆H₂₃NO
• 分子量: 245.365
• InChiKey: LJHIBIVAYHQPBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  DL-正缬氨酸 在 吡啶 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 正丁基锂 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 、 水 为溶剂， 反应 6.67h， 生成 (-)-1-(benzofuran-2-yl)-2-propylaminopentane
  参考文献：
  名称：

  对映选择性合成和绝对构型的（-）-1-（苯并呋喃-2-基）-2-丙基氨基戊烷（（-）-BPAP），一种高效的选择性儿茶酚胺能增强剂。

  摘要：

  描述了（-）-1-（苯并呋喃-2-基）-2-丙基氨基戊烷（（-）-BPAP）的对映选择性合成和绝对构型，这是一种高效且选择性的儿茶酚胺能活性增强剂（CAE）物质。合成方法包括苯并呋喃与（R）-N-甲苯磺酰基-2-丙基叠氮嗪或（R）-N-甲氧基-N-甲基降甲酰胺的偶联反应，然后对所得偶联产物进行适当的修饰。结果，（-）-BPAP证明具有R构型，其最终通过X射线晶体学分析得到证实。

  DOI：

  10.1016/s0968-0896(00)00341-2

文献信息

• Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
  申请人：Verheijen C. Jeroen

  公开号：US20050096387A1

  公开（公告）日：2005-05-05

  Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.

  碳酰基酯抑制胆碱酯酶活性，水解后释放出药理活性成分。在一种实施例中，碳酰基酯具有以下结构：其中A选自无取代芳基、取代芳基、无取代杂环芳基和取代杂环芳基的群组。碳酰基酯用于治疗个体的方法中。通过水解碳酰基酯获得的药理活性成分可以治疗例如神经系统疾病、胆碱能缺乏以及与药理活性成分缺乏相关的疾病或病症，例如乙酰胆碱。
• Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate
  申请人：Yoneda Fumio

  公开号：US20090124813A1

  公开（公告）日：2009-05-14

  There are provided a process for preparing an optically active aminopentane derivative that is promising as a psychotropic agent, an antidepressant agent, an antiparkinsonian agent, an anti-Alzheimer's agent, an apoptosis inhibitor, or the like; a novel optically active intermediate oxathiazolidine derivative very useful in the production of the aminopentane derivative; and process for the production thereof. The optically active aminopentane derivatives can be produced in an industrially advantageous manner from a novel optically active oxathiazolidine derivative represented by formula (5): wherein * indicates the position of an asymmetric carbon atom in the R or S configuration, and n is 0 or 1.

  提供了一种制备光学活性氨基戊烷衍生物的方法，该衍生物可作为精神药物、抗抑郁药物、抗帕金森病药物、抗阿尔茨海默病药物、凋亡抑制剂等，一种新型光学活性中间体噁嗪硫脲环衍生物，非常有用于制备氨基戊烷衍生物；以及其生产方法。光学活性氨基戊烷衍生物可以从新型光学活性噁嗪硫脲环衍生物中工业上优势地生产，该噁嗪硫脲环衍生物的化学式表示为（5）：其中*表示R或S构型的不对称碳原子的位置，n为0或1。
• PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE
  申请人：Yoneda Fumio

  公开号：US20100324300A1

  公开（公告）日：2010-12-23

  There are provided a process for preparing an optically active aminopentane derivative that is promising as a psychotropic agent, an antidepressant agent, an antiparkinsonian agent, an anti-Alzheimer's agent, an apoptosis inhibitor, or the like; a novel optically active intermediate oxathiazolidine derivative very useful in the production of the aminopentane derivative; and process for the production thereof. The optically active aminopentane derivatives can be produced in an industrially advantageous manner from a novel optically active oxathiazolidine derivative represented by formula (5): wherein * indicates the position of an asymmetric carbon atom in the R or S configuration, and n is 0 or 1.

  提供一种制备具有潜在作为精神药物、抗抑郁药、抗帕金森病药物、抗阿尔茨海默病药物、凋亡抑制剂等作用的光学活性氨基戊烷衍生物的方法；一种非常有用于氨基戊烷衍生物生产的新型光学活性内酰胺噻唑环衍生物；以及其生产方法。这些光学活性氨基戊烷衍生物可以从由式（5）表示的新型光学活性内酰胺噻唑环衍生物中以工业上的有利方式生产出来：其中*表示R或S构型的不对称碳原子的位置，n为0或1。
• NOVEL ETHYLAMINE DERIVATIVES
  申请人：Fujimoto Brothers Co., Ltd.

  公开号：EP0957080A1

  公开（公告）日：1999-11-17

  General formula (I):    (wherein R1 is hydrogen, hydroxyl, lower alkoxy or halogen; R2 is alkyl having 2 to 5 carbon atoms; R3 is hydrogen, alkyl having 2 to 5 carbon atoms, alkylcarbonyl having 2 to 5 carbon atoms, aryl having 6 to 10 carbon atoms or arylalkyl having 7 to 11 carbon atoms; A ring is bicyclic compound which consists of at least one benzene ring and may contain a saturated or unsaturated five- or six-membered ring which may or my not have heteroatoms, providing that when A ring is indole or 1,3-benzodioxole, R2 and R3 do not constitute, at the same time, two carbon atoms members, and when R3 is hydrogen. A ring is other bicyclic compound than indole and benzo[b]thiophene and R2 is alkyl having 3 to 5 carbon atoms) and pharmceutically acceptable acid addition salts thereof. These compounds are promising as psychtropic drugs, antidepressants, drugs for Parkinson's disease and/or drugs for Alzheimer's disease.

  通式（I）： (其中 R1 是氢、羟基、低级烷氧基或卤素；R2 是具有 2 至 5 个碳原子的烷基；R3 是氢、具有 2 至 5 个碳原子的烷基、具有 2 至 5 个碳原子的烷羰基、具有 6 至 10 个碳原子的芳基或具有 7 至 11 个碳原子的芳烷基；环是双环化合物，由至少一个苯环组成，可包含饱和或不饱和的五元或六元环，可带或不带杂质原子，条件是当环是吲哚或 1,3-苯并二恶茂时，R2 和 R3 不同时构成两个碳原子成员，且当 R3 为氢时。环是吲哚和苯并[b]噻吩以外的其他双环化合物，R2 是具有 3 至 5 个碳原子的烷基）及其药学上可接受的酸加成盐。这些化合物有望成为精神药物、抗抑郁药物、帕金森病药物和/或阿尔茨海默病药物。
• NOVEL OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE
  申请人：Fujimoto Brothers Co., Ltd.

  公开号：EP1052259A1

  公开（公告）日：2000-11-15

  (―)-1-(Benzofuran-2-yl)-2-propylaminopentane that contains no (+)-isomer substantially and shown by the following formula, and the pharmaceutically acceptable acid salts are disclosed. These compounds have excellent CAE effect (catecholaminergic activity enhancer effect) which is the enhancing action of neurotransmitter catecholamine release, and are useful as psychotropic composition, antidepressants, composition for treating Parkinson's disease and/or Alzheimer's disease.

  (-)-1-(苯并呋喃-2-基)-2-丙基氨基戊烷实质上不含(+)-异构体，如下式所示，公开了其药学上可接受的酸式盐。这些化合物具有优异的 CAE 效应（儿茶酚胺能活性增强效应），即增强神经递质儿茶酚胺释放的作用，可用作精神药物、抗抑郁药、治疗帕金森病和/或阿尔茨海默病的药物。